دورية أكاديمية
Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib.
| العنوان: | Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib. |
|---|---|
| المؤلفون: | de Velasco G; Department of Medical Oncology, Madrid, Spain. Electronic address: Gdvelasco.gdv@gmail.com., Alonso-Gordoa T; Department of Medical Oncology and Department of Genitourinary, Germ cell and Endocrine Tumors, Ramón y Cajal University Hospital and Ramón y Cajal Health Research Institute (IRYCIS), Madrid, Spain., Rodríguez-Vida A; Department of Medical Oncology, Hospital del Mar-CIBERONC, IMIM Research Institute, Barcelona, Spain., Anguera G; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Campayo M; Department of Medical Oncology, Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain., Pinto Á; Department of Medical Oncology, University Hospital La Paz, Madrid, Spain., Ortega EM; Department of Medical Oncology, University Hospital of Jaén, Jaén, Spain., Gallardo E; Department of Medical Oncology, University Hospital Parc Taulí, Institut d'Investigació i Innovació Parc Taulí, Sabadell, Spain., Núñez NF; Department of Medical Oncology, University Hospital Lucus Augusti, Lugo, Spain., García-Carbonero I; Department of Medical Oncology, University Hospital of Toledo, Toledo, Spain., Reig O; Department of Medical Oncology, Hospital Clínic and Translational Genomics and Targeted Therapeutics in Solid Tumors Group (IDIBAPS), Barcelona, Spain., Méndez-Vidal MJ; Department of Medical Oncology, University Hospital Reina Sofía, Maimónides Institute for Biomedical research of Córdoba (IMIBIC), Córdoba, Spain., Fernández-Calvo O; Department of Medical Oncology, University Hospital of Ourense, Ourense, Spain., Cassinello NV; Department of Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain., Torregrosa D; Department of Medical Oncology, University Hospital Dr. Peset, Valencia, Spain., López-Martín A; Medical Oncology Department, University Hospital Severo Ochoa, Madrid, Spain., Rosero A; Department of Medical Oncology, University Hospital Infanta Cristina, Parla, Madrid, Spain., Valiente PG; Department of Medical Oncology, University Hospital Marqués de Valdecilla, Santander, Spain., de España CG; Department of Medical Oncology, University Hospital Son Espases, Palma de Mallorca, Spain., Climent MA; Department of Medical Oncology, Fundación Instituto Valenciano de Oncología, Valencia, Spain., Santasusana MD; Department of Medical Oncology, Hospital Althaia, Manresa, Spain., Sánchez ÁR; Department of Medical Oncology, University Hospital of León, León, Spain., González IC; Department of Medical Oncology, Hospital Clínico Universitario, INCLIVA, University of Valencia, Valencia, Spain., Afonso R; Department of Medical Oncology, University Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain., García Del Muro X; Genitourinary Cancer and Sarcoma Unit, Institut Català d'Oncologia, Hospitalet, Barcelona, Spain., Casinello J; Department of Medical Oncology, University Hospital of Guadalajara, Guadalajara, Spain., Fernández-Parra EM; Department of Medical Oncology, University Hospital Valme, Sevilla, Spain., García Sánchez L; Department of Medical Oncology, University Hospital of Segovia, Segovia, Spain., Afonso J; Department of Medical Oncology, University Hospital of Ferrol, A Coruña, Spain., Polo SH; Department of Medical Oncology, University Hospital Fundación Alcorcón, Madrid, Spain., Asensio Ú; Medical Department, Pfizer Oncology, Madrid, Spain. |
| المصدر: | Clinical genitourinary cancer [Clin Genitourin Cancer] 2023 Jun; Vol. 21 (3), pp. e166-e174. Date of Electronic Publication: 2022 Dec 05. |
| نوع المنشور: | Observational Study; Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2009-> : [New York] : Elsevier Original Publication: Dallas, Tex. : Cancer Information Group, c2005- |
| مواضيع طبية MeSH: | Carcinoma, Renal Cell*/drug therapy , Carcinoma, Renal Cell*/secondary , Antineoplastic Agents*/therapeutic use , Kidney Neoplasms*/drug therapy , Kidney Neoplasms*/pathology, Humans ; Middle Aged ; Sunitinib/therapeutic use ; Retrospective Studies ; Indoles/therapeutic use ; Pyrroles/therapeutic use |
| مستخلص: | Introduction: The long-term clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) and a complete response (CR) to the tyrosine kinase inhibitor (TKI) sunitinib are poorly known. The characteristics of these patients could reveal previously undetected associations with clinical variables. Patients and Methods: This observational, retrospective study (ATILA) used data from a registry of patients with mRCC who had received first-line sunitinib and had achieved CR from 2007 to 2018 in Spain. Results: Sixty-two patients with CR were included; 48 patients (77.4%) received sunitinib in monotherapy and 14 (22.6%) combined with or followed by local treatment. Median age was 58.5 years (range, 32-81). Most patients (79.0%) had clear cell histology and had undergone previous nephrectomy (90.3%). The majority (70.2%) had an intermediate IMDC prognosis, 23% favorable and 7.0% poor. The median time on treatment with sunitinib was 28.2 months (IQR, 16.7-41.0) and the median time to CR was 10.9 months (IQR, 7.2-19.3). After a median follow-up of 8 years (range, 3-13 years), the median PFS was not reached. The overall median duration of complete response was 64.1 months (IQR, 32.2-99.4). The tolerance and safety profile of sunitinib was consistent with previous reports. Conclusion: Durable CR to sunitinib was observed in patients regardless the prognosis group, metastasis site or histology type, with 75% of patients remaining in CR after 10 years. Clinicaltrials: gov: NCT03916458. Competing Interests: Disclosures G.d.V. received research grants from Pfizer, Roche, and Ipsen; consulting or honoraria fees from Ipsen, Pfizer, Roche, Bayer, Astellas, BMS, MSD and Merck. T.A.G. received research grants from Pfizer, Roche, and Ipsen; consulting fees from Ipsen, Pfizer, Roche, Sanofi, Bayer, Astellas, Janssen-Cilag, BMS, and EISAI; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Ipsen, Pfizer, Eisai, and Merck; and support for attending meetings and/or travel from Pfizer, Sanofi, BMS, and IPSEN. A.R.-V. served in advisory boards for MSD, Pfizer, BMS, Astellas, Janssen, Bayer, Clovis and Roche; received honoraria or travel expenses from Pfizer, MSD, Astellas, BMS, Janssen, Astra Zeneca, Roche, Bayer, and Sanofi Aventis; and research funding from Takeda, Pfizer, and Merck. G.A.P. served in speaker bureaus for Ipsen, BMS, Roche, and Janssen. M.C. served in advisory or consultancy roles for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, EUSA Pharma, Lilly, Roche; received honoraria for lectures for Abbot, Bristol-Myers Squibb, EUSA Pharma, Ipsen, Novartis, Pfizer, Pierre Fabre, Roche; holds institutional financial interests in Astra Zeneca, Merck, Pfizer, Roche, and received travel expenses from Ipsen, Lilly, Merck, Pfizer, and Pierre Fabre. A.P. received research grants from Pfizer and BMS; advisory boards/speaker fees from Pfizer, BMS, Ipsen, Roche, Merck, MSD, Janssen, Astellas, Bayer, Sanofi; and travel expenses from Pfizer, BMS, Janssen and Roche. E.G. received grant support from Astellas, Janssen, Sanofi, Bayer, Ipsen, Ferrer, Pfizer, Roche, GSK and BMS; consulting fees from Sanofi, Janssen, Astellas, Bayer, Ipsen, Pfizer, Roche, Novartis, Eisai, EUSA Pharma, BMS, AstraZeneca, Merck, Rovi, Daiichi Sankyo and Techdow; payment or honoraria for lectures, presentations, speakers’ bureaus, man-uscript writing, or educational events from Astellas, Janssen, Sanofi, Bayer, Ipsen, Pfizer, Roche, BMS, Rovi, Daiichi Sankyo, Leo Pharma, Menarini, Eisai, MSD, Boehringer Ingelheim, Merck, EUSA Pharma and Novartis; support for attending meetings and/or travel from As-tellas, Janssen, Sanofi, BMS, Bayer, Ipsen, Roche, Novartis, Pierre Fabre, Pfizer and Eisai. N.F.N. received support from Roche, BMS, Boehringuer, Sanofi, Bayer, Astra Zeneca, Janssen, MSD, Lilly, Pfizer and IPSEN. I.C.-G. participated in advisory boards of Pfizer, EISAI and BMS. O.R. had consulting or advisory roles with BMS, EISAI, Ipsen; received travel and accommodations support from Ipsen and Pfizer. M.J.M. received honoraria and /or travel support from Janssen-Cilag, Bayer healthcare, Sanofi Aventis, Astellas Medivation, Roche, Ipsen, EISAI, Novartis and Pfizer; advisory boards and speaking for: Pfizer, Astellas, Roche, Ipsen, BMS, Eusa Pharma, Sanofi, Novartis, Janssen andPierre Fabre. N.V.C. received consultant fees from Janssen; speaking fees from Sanofi, Astra Zeneca, Astellas, Janssen, Roche, MSD, Ipsen; and travel support from Pfizer, Pierre Fabre, BMS. A.L.M. received support for attending meetings from Roche and MSD. C.G.d.E. has held consultant or advisory roles with Janssen, Sanofi, Bayer, Astellas; speaking roles from Janssen, Sanofi, Bayer, Astellas, Roche, Ipsen, Pfizer; and other support from Janssen, Sanofi and Roche. M.A.C. has held consulting or advisory role with BMS, MSD, Bayer, EUNSA, Pfizer, Roche, Janssen, Pierre Fabre, Ipsen; received travel expenses from Janssen, Astellas, Roche, Ipsen, and MSD. A.R.S. held consulting or advisory roles for Roche, Bristol, Sanofi, Merck, Ipsen and Eisai. I.C.G. has served as consultant or advisory board to Pzifer, Bristol-Myers Squibb, Ipsen, Roche and EusaPharma; has served as speaker to Pfizer, Bristol-Myers Squibb and Ipsen; and received travel and/or accommodation grants from Pfizer. R.A. has participated in advisory boards for Pfizer, Roche, Sanofi and Servier. X.G.d.M. has participated in advisory boards or as invited speaker for Astellas, BMS, Ipsen, Roche, Eusa Pharma, Eisai, Pfizer and Pharmamar. J.C. reports support from Janssen, Roche, AstraZéneca, Astellas, BMS, Pfizer, Sanofi, and Novartis. J.A. received advisory boards/speaker fees from Novartis, Pfizer, Merck, Roche, BMS; and travel and accommodations from AstraZeneca, BMS, Pfizer, Astellas and Sanofi. S.H.P. participated in advisory boards and as speaker for GSK, Clovis, Astra-Zeneca/MSD and Pfizer. Ú.A. is an employee of Pfizer. All other authors report no conflicts of interests. (Copyright © 2022 Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Complete response; Metastatic renal cell carcinoma; Renal cell carcinoma; Sunitinib; Tyrosine kinase inhibitor |
| سلسلة جزيئية: | ClinicalTrials.gov NCT03916458 |
| المشرفين على المادة: | V99T50803M (Sunitinib) 0 (Antineoplastic Agents) 0 (Indoles) 0 (Pyrroles) |
| تواريخ الأحداث: | Date Created: 20230107 Date Completed: 20230529 Latest Revision: 20230529 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/j.clgc.2022.11.021 |
| PMID: | 36610891 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1938-0682 |
|---|---|
| DOI: | 10.1016/j.clgc.2022.11.021 |